Clinical trials: Rivaroxaban
Bariatric Surgery, Morbid Obesity
Pharmacokinetics of Rivaroxaban After Bariatric Surgery
Data on pharmacokinetics of rivaroxaban after bariatric surgery and in morbid obesity are sparse. The aim of this study is to assess the pharmacokinetic and pharmacodynamic parameters of rivaroxaban, used at a therapeutic…
- Trial name
- ABSORB (NCT04180436)
- Testing
- rivaroxaban 20 mg once daily 8 days
- Where
- France
- Volunteers
- 67 people, healthy volunteers welcome
- Sponsor
- University Hospital, Brest
COVID-19
Preventing Cardiac Complication of COVID-19 Disease With Early Acute Coronary Syndrome Therapy: A Randomised Controlled Trial.
The outbreak of a novel coronavirus (SARS-CoV-2) and associated COVID-19 disease in late December 2019 has led to a global pandemic. At the time of writing, there have been 150 000 confirmed cases and 3500 deaths.
- Trial name
- C-19-ACS (NCT04333407)
- Testing
- Aspirin 75mg, Clopidogrel 75mg, Rivaroxaban 2.5 MG
- Where
- United Kingdom
- Volunteers
- 320 people
- Sponsor
- Imperial College London
Antiphospholipid Syndrome, Systemic Lupus Erythematosus
RIvaroxaban for Stroke Patients With AntiPhospholipid Syndrome
Rivaroxaban versus warfarin for stroke patients with antiphospholipid syndrome, with or without SLE (RISAPS): a randomised, controlled, open-label, phase IIb, non-inferiority proof of principle trial.
- Conditions
- Antiphospholipid Syndrome, Systemic Lupus Erythematosus, Stroke, Ischemic Stroke
- Trial name
- RISAPS (NCT03684564)
- Testing
- Rivaroxaban, Warfarin
- Where
- 6 sites in United Kingdom
- Volunteers
- 43 people
- Sponsor
- University College, London
Atrial Fibrillation
Pleotropic Effect of New Oral Anticoagulants
Atrial fibrillation (AF) has been known to have several pathophysiologic mechanisms including endothelial dysfunction of heart and vessel.
- Trial name
- NCT02544932
- Testing
- dabigatran, ribaroxaban, Warfarin
- Where
- South Korea
- Volunteers
- 55 people, healthy volunteers welcome
- Sponsor
- Kyunghee University Medical Center
Venous Thromboembolic Disease, Pulmonary Embolism
CHIPs-VTE Study in Hospitalized Patients With Lung Cancer
Venous thromboembolism (VTE) is a common complication of malignancies, in particular to lung cancer. Patients with lung cancer in surgical and medical departments are at high risk of VTE development.
- Conditions
- Venous Thromboembolic Disease, Pulmonary Embolism, Deep Venous Thrombosis
- Trial name
- NCT04158973
- Testing
- Bleeding-risk based prophylaxis strategy during hospitalization and extended pharmacological treatment after discharge, Routine VTE prophylaxis in hospital
- Volunteers
- 3,200 people
- Sponsor
- China-Japan Friendship Hospital
Cerebral Venous Thrombosis
Steroid for Treatment of Acute/Subacute Severe Cerebral Venous Thrombosis.
The cohort study aims to evaluate the efficacy and safety of steroids combined with anticoagulant therapy compared to standard anticoagulant therapy in acute/subacute severe cerebral venous thrombosis.
- Trial name
- NCT05990894
- Testing
- Methylprednisolone
- Where
- China
- Volunteers
- 170 people
- Sponsor
- Xuanwu Hospital, Beijing
Embolism, Atrial Fibrillation and Venous Thrombosis
Bioequivalence Study of Rivaroxaban in Japanese Healthy Adult Male Subjects
The objectives of this study are to establish the bioequivalence between rivaroxaban tablet 10mg and rivaroxaban granule formulation 10mg, and to assess the safety and tolerability of rivaroxaban 10mg in healthy adult male…
- Trial name
- NCT02537405
- Testing
- Rivaroxaban (BAY 59-7939), Rivaroxaban (Xarelto, BAY 59-7939)
- Where
- Japan
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Bayer
Post Thrombotic Syndrome, Chronic Thromboembolic Pulmonary Hypertension
Long Term Outcomes of Venous Thromboembolism
This prospective observational follow-up study is designed to assess the long-term outcomes after Venous thromboembolism (VTE) and to assess the effect of the new oral anticoagulant (NOAC) rivaroxaban on the prevalence of…
- Conditions
- Post Thrombotic Syndrome, Chronic Thromboembolic Pulmonary Hypertension, Venous Thrombosis
- Trial name
- LOVE (NCT02268630)
- Where
- 3 sites in Norway
- Volunteers
- 460 people
- Sponsor
- Ostfold Hospital Trust
Venous Thromboembolism, Menstruation
RAMBLE - Rivaroxaban vs. Apixaban for Heavy Menstrual Bleeding
A large proportion of women with menstruating potential with newly diagnosed VTE or atrial fibrillation, treated with apixaban will have less menstrual blood loss than patients randomized to rivaroxaban.
- Trial name
- (RAMBLE) (NCT02829957)
- Testing
- Apixaban, Rivaroxaban
- Where
- 2 sites in United States
- Volunteers
- 19 people
- Sponsor
- Indiana University
Prevention of Atherothrombotic Events, Coronary Artery Disease (CAD)
Study to Learn More About the Safety and Effectiveness of Rivaroxaban (Xarelto) When Given Together With Acetylsalicylic Acid to Indian People With Narrowing of the Arteries of the Heart (CAD) and/or With Reduced Blood Flow in the Arteries of the Legs and Arms With Symptoms (Symptomatic PAD)
This is an observational study in which data from Indian people with coronary artery disease and / or symptomatic peripheral artery disease who will be receiving the drug rivaroxaban (Xarelto) are studied.
- Conditions
- Prevention of Atherothrombotic Events, Coronary Artery Disease (CAD), Symptomatic Peripheral Artery Disease (Symptomatic PAD)
- Trial name
- NCT04298567
- Testing
- Rivaroxaban (Xarelto,Bay 59-7939), Acetylsalicylic acid(ASA)
- Where
- India
- Volunteers
- 300 people
- Sponsor
- Bayer
Heart Failure, Respiratory Insufficiency
A Study of Rivaroxaban (JNJ-39039039) on the Venous Thromboembolic Risk in Post-Hospital Discharge Patients
The purpose of this study is to evaluate the efficacy and safety of rivaroxaban compared with placebo in the prevention of symptomatic venous thromboembolism (VTE) events and VTE-related death post-hospital discharge in…
- Conditions
- Heart Failure, Respiratory Insufficiency, Stroke Acute, Infectious Diseases
- Trial name
- MARINER (NCT02111564)
- Testing
- Rivaroxaban, 10 mg, Rivaroxaban, 7.5 mg
- Where
- 593 sites in United States, Argentina and 35 more
- Volunteers
- 12,024 people
- Sponsor
- Janssen Research & Development, LLC
Venous Thromboembolism, Cancer
Primary Thromboprophylaxis in Patients With Malignancy and Central Venous Catheters
The purpose of the full trial is to determine the efficacy and safety of prophylactic dose rivaroxaban to prevent VTE among cancer patients with CVC.
- Trial name
- TRIM-Line (NCT05029063)
- Testing
- Rivaroxaban 10 MG
- Where
- 11 sites in Canada
- Volunteers
- 1,828 people
- Sponsor
- Ottawa Hospital Research Institute
Glioma, Malignant
Efficacy and Safety of Rivaroxaban in the Prevention of Venous Thromboembolism in Glioma Patients
Glioma is a common brain tumor with a high risk of venous thromboembolism during treatment, especially in the months after surgery.
- Trial name
- NCT06196918
- Testing
- Rivaroxaban 10 MG
- Where
- 8 sites in China
- Volunteers
- 320 people
- Sponsor
- Nanfang Hospital, Southern Medical University
Sickle Cell Anemia, Sickle Cell-Beta0-Thalassemia
The Effect of Rivaroxaban in Sickle Cell Disease
The primary study hypothesis is that inhibition of factor Xa with rivaroxaban will reduce inflammation, coagulation and endothelial cell activation, and improve microvascular blood flow in patients with sickle cell disease (SCD)…
- Trial name
- NCT02072668
- Testing
- rivaroxaban
- Where
- United States
- Volunteers
- 14 people
- Sponsor
- University of North Carolina, Chapel Hill
Venous Thromboembolism, Major Bleed
Direct Oral Anticoagulants and Venous Thromboembolism
The purpose of this study is to determine whether use of direct oral anticoagulants (DOACs) is associated with an increased risk of major bleeding compared to warfarin use, for the treatment of venous thromboembolism (VTE).
- Trial name
- NCT02833987
- Testing
- Apixaban (ATC B01AF02), Dabigatran (ATC B01AE07), Rivaroxaban (ATC B01AF01)
- Where
- Canada
- Volunteers
- 59,525 people
- Sponsor
- Canadian Network for Observational Drug Effect Studies, CNODES
Anticoagulation
Efficacy and Safety of Rivaroxaban in the Early Postoperative Period for Patients With Bioprosthetic Valves
this study aims to comprehensively evaluate the efficacy and safety profiles of rivaroxaban and warfarin during the initial postoperative period following surgical bioprosthetic valve in patients.
- Trial name
- NCT06476301
- Testing
- Rivaroxaban
- Volunteers
- 250 people
- Sponsor
- RenJi Hospital
Acute Exacerbation Copd, Venous Thromboembolism
Study of Prophylactic Effect of Rivaroxaban on Venous Thromboembolism in AECOPD
AECOPD increases the risk of VTE.VTE prevention is a long way to go for high-risk VTE patients in China.The incidence of AECOPD complicated with VTE in Asian population is high and the mortality rate is high.Rivaroxaban, a new…
- Trial name
- SUPREME (NCT03277001)
- Testing
- Rivaroxaban, Enoxaparin
- Where
- China
- Volunteers
- 438 people
- Sponsor
- Huashan Hospital
Atrial Fibrillation
Non-interventional, Retrospective Cohort Study to Explore OAC Treatment in Korea
The primary purpose of this study is to evaluate comparative effectiveness and safety outcomes of therapies to prevent thromboembolic events in patients with nonvalvular atrial fibrillation by using Korean nationwide health…
- Trial name
- NCT03572972
- Testing
- Apixaban, Dabigatran, Rivaroxaban
- Where
- South Korea
- Volunteers
- 64,684 people
- Sponsor
- Pfizer
Cardiovascular Diseases
Reveal Transition - A Mechanistic Study in Transition / Stabilized Phase of CAD
Longterm oral anticoagulation with very low dose rivaroxaban (2.5mg bid) in combination with aspirin has been shown superior over standard aspirin monotherapy in patients with stable coronary artery disease (CAD) in the COMPASS…
- Trial name
- RevealTrans (NCT04032665)
- Testing
- Rivaroxaban
- Where
- Germany
- Sponsor
- University Hospital Tuebingen
Non-valvular Atrial Fibrillation (NVAF)
Study to Gain Information on the Drug Xarelto for the Prevention of Brain Attack and Blockage of an Artery in the Non-central Nervous System Due to Irregular Heartbeat in Taiwanese Patients Suffering From Decreased Renal Function
In this study researchers want to learn more about on the safety of the drug Xarelto. The study will enroll patients for whom the treating doctor are prescribing Xarelto for the prevention of brain attack or the prevention of…
- Trial name
- XARETO (NCT04356989)
- Testing
- Rivaroxaban (Xarelto, BAY59-7939)
- Where
- Taiwan
- Volunteers
- 493 people
- Sponsor
- Bayer